Going Public Without an IPO: Examples from the Biotech Industry
Valuations that made “sense” in 2000 have been reduced, forcing many “cram-down” financings that are painful for investors and management. Business models can and need to be as adept, flexible and creative as the science that drives our industry. There are alternative ways to “go public” that do not involve traditional capital infusion or reverse mergers and which can provide a short-term exit strategy for investors while allowing new technologies to flourish.
In this panel discussion, Rick Burgoon (V.P. Business Operations and Board member of Epiomed), Court Turner (Partner at Avalon Ventures) and Jack Florio (Sr VP Brinson Patrick Securities Corporation) will discuss pros and cons and methodologies of an innovative approach to fund-raising involving equity arrangements with development partners and the shortened S1 registration process. Div Gupta (Partner at at Latham & Watkins LLP) will moderate the discussion.
Date/Time Start:: 2/22/2011 6:00pm
Date/Time End:: 2/22/2011 8:00pm
Cost to Attend: